IBD INNOVATE 2025
9-10 April 2025
New York, USA
Adam Wilkinson attending and presenting a poster.
At Microbiotica, we are translating clinic-led microbiome science into transformative life-changing medicines.
About Us
Building a clinical-stage biopharmaceutical company supported by leaders in precision microbiome science and medicine, and a strong syndicate of investors.
Pipeline
Advancing our pipeline of clinic-ready defined live biotherapeutic products, with known mechanisms of action, for immuno-oncology and inflammatory bowel disease.
Platform
Leveraging our clinic-led discovery platform to enable precise identification of bacteria linked to patient outcomes and targeting of specific patient populations.
News
- Microbiotica presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma 26 February 2025
- Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis 21 February 2025
Events
AACR Annual Meeting 2025
25-30 April 2025
Chicago, USAMat Robinson attending and presenting a poster.
DDW 2025
3-6 May 2025
San Diego, USATim Sharpington attending and presenting a poster.
Microbiotica is a clinic-ready biopharmaceutical company developing a pipeline of orally-delivered live biotherapeutic products (LBPs) composed of highly-defined bacterial strains for therapeutic applications in immuno-oncology (IO) and inflammatory bowel disease (IBD).
